RU2019127021A - Новые молочнокислые бактерии и их применение - Google Patents
Новые молочнокислые бактерии и их применение Download PDFInfo
- Publication number
- RU2019127021A RU2019127021A RU2019127021A RU2019127021A RU2019127021A RU 2019127021 A RU2019127021 A RU 2019127021A RU 2019127021 A RU2019127021 A RU 2019127021A RU 2019127021 A RU2019127021 A RU 2019127021A RU 2019127021 A RU2019127021 A RU 2019127021A
- Authority
- RU
- Russia
- Prior art keywords
- kccm11961p
- kccm11962p
- lactobacillus plantarum
- bifidobacterium longum
- pharmaceutical composition
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title 1
- 241001608472 Bifidobacterium longum Species 0.000 claims 14
- 240000006024 Lactobacillus plantarum Species 0.000 claims 14
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims 14
- 229940009291 bifidobacterium longum Drugs 0.000 claims 14
- 229940072205 lactobacillus plantarum Drugs 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 208000026935 allergic disease Diseases 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 6
- 235000013305 food Nutrition 0.000 claims 5
- 239000000284 extract Substances 0.000 claims 4
- 239000006166 lysate Substances 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims 2
- 108020004465 16S ribosomal RNA Proteins 0.000 claims 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 claims 2
- 206010002199 Anaphylactic shock Diseases 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 2
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 claims 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 229920001202 Inulin Polymers 0.000 claims 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 2
- 206010033078 Otitis media Diseases 0.000 claims 2
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 2
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 2
- 229940045110 chitosan Drugs 0.000 claims 2
- 229940040387 citrus pectin Drugs 0.000 claims 2
- 239000009194 citrus pectin Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000000959 ear middle Anatomy 0.000 claims 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 claims 2
- 229940093496 esculin Drugs 0.000 claims 2
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 claims 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims 2
- 230000002134 immunopathologic effect Effects 0.000 claims 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 2
- 229940029339 inulin Drugs 0.000 claims 2
- 229960002160 maltose Drugs 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 claims 2
- 229940120668 salicin Drugs 0.000 claims 2
- 229960002920 sorbitol Drugs 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229960004793 sucrose Drugs 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 claims 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 1
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 claims 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 claims 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- PYMYPHUHKUWMLA-VAYJURFESA-N aldehydo-L-arabinose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VAYJURFESA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 229940089837 amygdalin Drugs 0.000 claims 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 claims 1
- 229960000271 arbutin Drugs 0.000 claims 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 claims 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 claims 1
- 229940050410 gluconate Drugs 0.000 claims 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D8/00—Methods for preparing or baking dough
- A21D8/02—Methods for preparing dough; Treating dough prior to baking
- A21D8/04—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D8/00—Methods for preparing or baking dough
- A21D8/02—Methods for preparing dough; Treating dough prior to baking
- A21D8/04—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
- A21D8/045—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes with a leaven or a composition containing acidifying bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/127—Fermented milk preparations; Treatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (22)
1. Bifidobacterium longum IM55 KCCM11961P.
2. Lactobacillus plantarum IM76 KCCM11962P.
3. Bifidobacterium longum IM55 KCCM11961P по п. 1, где указанный Bifidobacterium longum IM55 KCCM11961P содержит последовательность 16S rDNA под SEQ ID NO: 1.
4. Bifidobacterium longum IM55 KCCM11961P по п. 1, где указанный Bifidobacterium longum IM55 KCCM11961P в качестве источника углерода использует D-глюкозу, D-маннит, D-лактозу, D-сахарозу, D-мальтозу, салицин, D-ксилозу, L-арабинозу, цитрат железа с эскулином, D-рафинозу и D-сорбит.
5. Lactobacillus plantarum IM76 KCCM11962P по п. 2, где указанный Lactobacillus plantarum IM76 KCCM11962P содержит последовательность 16S rDNA под SEQ ID NO: 2.
6. Lactobacillus plantarum IM76 KCCM11962P по п. 2, где указанный Lactobacillus plantarum IM76 KCCM11962P в качестве источника углерода использует L-арабинозу, D-рибозу, D-галактозу, D-глюкозу, D-фруктозу, D-маннозу, маннит, сорбит, N-ацетилглюкозамин, амигдалин, арбутин, эскулин, салицин, целлобиозу, мальтозу, лактозу, мелибиозу, сахарозу, трегалозу, рафинозу, гентиобиозу, D-туранозу и глюконат.
7. Фармацевтическая композиция для предупреждения или лечения аллергических заболеваний, содержащая Bifidobacterium longum IM55 KCCM11961P, Lactobacillus plantarum IM76 KCCM11962P или их смеси.
8. Фармацевтическая композиция по п. 7, где указанный Bifidobacterium longum IM55 KCCM11961P представляет собой его живую клетку, его неживую клетку, продукт его культивирования, его лизат или его экстракт.
9. Фармацевтическая композиция по п. 7, где указанный Lactobacillus plantarum IM76 KCCM11962P представляет собой его живую клетку, его неживую клетку, продукт его культивирования, его лизат или его экстракт.
10. Фармацевтическая композиция по п. 7, где указанные аллергические заболевания представляют собой по меньшей мере одно заболевание, выбранное из группы, включающей ринит, атопию, астму, атопический дерматит, аллергический конъюнктивит, аллергический отит среднего уха, крапивницу и анафилактический шок.
11. Фармацевтическая композиция по п. 7, где указанная фармацевтическая композиция дополнительно содержит по меньшей мере одно вещество, выбранное из группы, включающей хитозан, инулин и цитрусовый пектин.
12. Пищевая композиция для предупреждения или облегчения тяжести аллергических заболеваний, содержащая Bifidobacterium longum IM55 KCCM11961P, Lactobacillus plantarum IM76 KCCM11962P или их смеси.
13. Пищевая композиция по п. 12, где указанный Bifidobacterium longum IM55 KCCM11961P представляет собой его живую клетку, его неживую клетку, продукт его культивирования, его лизат или его экстракт.
14. Пищевая композиция по п. 12, где указанный Lactobacillus plantarum IM76 KCCM11962P представляет собой его живую клетку, его неживую клетку, продукт его культивирования, его лизат или его экстракт.
15. Пищевая композиция по п. 12, где указанные аллергические заболевания представляют собой по меньшей мере одно заболевание, выбранное из группы, включающей ринит, атопию, астму, атопический дерматит, аллергический конъюнктивит, аллергический отит среднего уха, крапивницу и анафилактический шок.
16. Пищевая композиция по п. 12, где указанная фармацевтическая композиция дополнительно содержит по меньшей мере одно вещество, выбранное из группы, включающей хитозан, инулин и цитрусовый пектин.
17. Фармацевтическая композиция для предупреждения или лечения иммунопатологических заболеваний или воспалительных заболеваний, содержащая Bifidobacterium longum IM55 KCCM11961P, Lactobacillus plantarum IM76 KCCM11962P или их смеси.
18. Фармацевтическая композиция для предупреждения или лечения иммунопатологических заболеваний или воспалительных заболеваний по п. 17, где указанные воспалительные заболевания представляют собой колит.
19. Способ предупреждения или лечения аллергических заболеваний, включающий стадию введения индивидууму Bifidobacterium longum IM55 KCCM11961P, Lactobacillus plantarum IM76 KCCM11962P или их смесей.
20. Применение Bifidobacterium longum IM55 KCCM11961P, Lactobacillus plantarum IM76 KCCM11962P или их смесей при предупреждении или лечении аллергических заболеваний.
21. Применение Bifidobacterium longum IM55 KCCM11961P, Lactobacillus plantarum IM76 KCCM11962P или их смесей при получении лекарственного средства для предупреждения или лечения аллергических заболеваний.
22. Композиция, содержащая Bifidobacterium longum IM55 KCCM11961P, Lactobacillus plantarum IM76 KCCM11962P или их смеси, для применения при предупреждении или лечении аллергических заболеваний.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170013632 | 2017-01-31 | ||
KR10-2017-0013632 | 2017-01-31 | ||
PCT/KR2018/001359 WO2018143678A1 (ko) | 2017-01-31 | 2018-01-31 | 신규 유산균 및 이의 용도 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2021118078A Division RU2790442C2 (ru) | 2017-01-31 | 2018-01-31 | Новый штамм lactobacillus plantarum, композиции, содержащие его, и связанный с ним способ и его применение |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019127021A true RU2019127021A (ru) | 2021-03-02 |
RU2019127021A3 RU2019127021A3 (ru) | 2021-03-02 |
RU2752157C2 RU2752157C2 (ru) | 2021-07-23 |
Family
ID=63040871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019127021A RU2752157C2 (ru) | 2017-01-31 | 2018-01-31 | Новые молочнокислые бактерии и их применение |
Country Status (11)
Country | Link |
---|---|
US (2) | US11660321B2 (ru) |
JP (2) | JP6839298B2 (ru) |
KR (2) | KR101999259B1 (ru) |
CN (2) | CN116676222A (ru) |
AU (2) | AU2018216532B2 (ru) |
BR (1) | BR112019015806A2 (ru) |
CA (2) | CA3178100A1 (ru) |
MX (2) | MX2019009079A (ru) |
RU (1) | RU2752157C2 (ru) |
SG (3) | SG10202107425VA (ru) |
WO (1) | WO2018143678A1 (ru) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7015674B2 (ja) * | 2017-10-27 | 2022-02-15 | 日清食品ホールディングス株式会社 | 制御性t細胞の分化誘導剤及び分化誘導方法 |
CN109498660A (zh) * | 2018-11-23 | 2019-03-22 | 江南大学 | 一种能够缓解特应性皮炎的植物乳杆菌ccfm8610的应用 |
KR102074445B1 (ko) * | 2018-12-12 | 2020-02-06 | 주식회사 비피도 | 류마티스관절염 개선, 예방 또는 치료를 위한 비피도박테리움 롱검 rapo 균주 및 이를 포함하는 조성물 |
CN109652349B (zh) * | 2019-02-25 | 2021-03-02 | 江南大学 | 一株能够缓解特应性皮炎的长双歧杆菌及其应用 |
WO2021040335A1 (ko) * | 2019-08-23 | 2021-03-04 | 연세대학교 산학협력단 | 활성산소 조건에서 저항능을 가진 신규한 공생 미생물 균주 및 이의 용도 |
KR102254310B1 (ko) * | 2019-10-02 | 2021-05-21 | 주식회사 고바이오랩 | 락토바실러스 애시도필러스 kbl409 균주 및 그 용도 |
KR102263698B1 (ko) * | 2019-11-29 | 2021-06-09 | 롯데칠성음료주식회사 | 아토피 피부염 완화 또는 개선 효과를 가지는 락토바실러스 플랜타럼 lrcc5195 균주 및 이소말토올리고당 복합체 |
CN110960562B (zh) * | 2019-12-31 | 2020-10-16 | 广州市爱百伊生物技术有限公司 | 抗敏作用的益生菌组合物 |
JP6995411B2 (ja) * | 2020-02-18 | 2022-02-21 | AuB株式会社 | 新規ビフィドバクテリウム属細菌及びそれを含む組成物 |
CN111419883B (zh) * | 2020-03-13 | 2023-08-04 | 广州柏芳生物科技有限公司 | 一种治疗过敏性鼻炎的鼻腔喷剂的制备方法 |
KR102162470B1 (ko) | 2020-03-19 | 2020-10-06 | 주식회사 비피도 | 비피도박테리움 슈도카테눌라튬 c-rapo (kctc13986bp), 비피도박테리움 비피덤 att (kctc13474bp) 균주를 포함하는 쇼그렌증후군 억제용 식품 조성물 및 약학 조성물 |
CN111647526B (zh) * | 2020-05-18 | 2022-08-05 | 深圳华大基因农业控股有限公司 | 植物乳杆菌sd-h9、其益生菌菌剂及其应用 |
KR102154255B1 (ko) * | 2020-05-22 | 2020-09-09 | (주)녹십자웰빙 | 유산균을 함유하는 미세먼지 자극에 의한 호흡기 질환 또는 염증 질환 치료용 조성물 |
JP7143044B2 (ja) * | 2020-06-23 | 2022-09-28 | カゴメ株式会社 | アレルギー性鼻炎症状改善用組成物、アレルギー性鼻炎症状に起因するqol低下改善用組成物、及び、アレルギー性鼻炎症状に起因するくしゃみ抑制用組成物 |
JP2022042042A (ja) * | 2020-09-02 | 2022-03-14 | 日清食品ホールディングス株式会社 | Il-17の産生を抑制するビフィズス菌 |
KR20220069248A (ko) * | 2020-11-20 | 2022-05-27 | 가톨릭대학교 산학협력단 | 비피도박테리움 속을 유효성분으로 포함하는 피부경화증에 대한 테라그노시스용 조성물 |
TW202241477A (zh) * | 2020-12-16 | 2022-11-01 | 日商明治股份有限公司 | 腦組織之發炎改善用組成物 |
WO2022171654A1 (en) * | 2021-02-09 | 2022-08-18 | Lactobio A/S | Method for treating atopic disorders |
KR102268125B1 (ko) * | 2021-02-09 | 2021-06-22 | 주식회사 락토메이슨 | 한국인 영유아 유래 신규한 비피도박테리움 롱검 lm1024 균주, 및 상기 균주 또는 이의 배양물을 포함하는 월경전 증후군 완화용 조성물 |
KR102294442B1 (ko) | 2021-02-17 | 2021-08-27 | 주식회사 메디오젠 | 영유아 유래 유산균 락토바실러스 플란타럼 mg4555 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물 |
KR102294437B1 (ko) | 2021-02-17 | 2021-08-27 | 주식회사 메디오젠 | 영유아 유래 유산균 락토바실러스 플란타럼 mg4553 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물 |
KR102360233B1 (ko) * | 2021-03-26 | 2022-02-09 | (주)바이오일레븐 | 구강질환 예방 또는 개선 효과를 가지는 락토바실러스 퍼멘텀 균주 및 이의 용도 |
KR102445903B1 (ko) * | 2021-07-06 | 2022-09-22 | 롯데제과 주식회사 | 혈당 상승 저해 및 스트레스 조절 효과가 우수한 열처리된 락토바실러스 플랜타럼 lrcc5314 균주 및 용도 |
CN115466689B (zh) * | 2022-02-09 | 2023-06-16 | 中国科学技术大学 | 用于预防和/或治疗代谢类疾病的益生菌组合物及其应用 |
CN115181698B (zh) * | 2022-06-28 | 2023-09-08 | 广东粤港澳大湾区国家纳米科技创新研究院 | 一种益生菌组合物及应用 |
CN115364127A (zh) * | 2022-07-06 | 2022-11-22 | 华南理工大学 | 一种对免疫抑制小鼠具有调节作用的植物乳杆菌与益生元复合物 |
KR102568093B1 (ko) * | 2023-02-07 | 2023-08-22 | 주식회사 바이오뱅크힐링 | 비피도박테리움 롱검을 유효성분으로 포함하는 알레르기 질환의 예방 또는 치료용 조성물 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID29150A (id) * | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
KR20050076374A (ko) | 2004-01-20 | 2005-07-26 | 김수남 | 아토피와 항알러지 및 장내유해세균의 암모니아 생산을저해하는 활성을 갖는 두류 유산균 발효물을 함유한기능성 제품 및 그의 제조방법 |
JP5273695B2 (ja) * | 2005-03-03 | 2013-08-28 | 株式会社明治 | ビフィズス菌を有効成分とするアレルギー予防および/または治療剤 |
BRPI0616962B8 (pt) | 2005-10-06 | 2021-05-25 | Probi Ab | uso de lactobacillus para o tratamento de doenças autoimunes |
KR100715730B1 (ko) | 2005-11-15 | 2007-05-08 | 연세대학교 산학협력단 | 유해 병원성 미생물에 대한 항균활성을 갖는 신규비피도박테리움 롱검 a24 |
ES2381211T3 (es) | 2006-02-15 | 2012-05-24 | Nestec S.A. | Uso del Bifidobacterium longum para prevenir y tratar inflamaciones |
KR20080075971A (ko) | 2007-02-14 | 2008-08-20 | (주)네오팜 | 프로바이오틱스 복합 제제 |
PL2134833T3 (pl) * | 2007-03-28 | 2016-09-30 | Probiotyczny szczep Bifidobacterium | |
DK2203551T3 (da) * | 2007-10-20 | 2013-10-28 | Univ Liege | Bifidobakterieart |
CN104784694A (zh) * | 2009-06-19 | 2015-07-22 | 杜邦营养生物科学有限公司 | 治疗糖尿病及相关病症的双歧杆菌 |
KR101178217B1 (ko) * | 2009-10-28 | 2012-09-07 | 씨제이제일제당 (주) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 |
EP2498789B1 (en) * | 2009-11-11 | 2016-06-22 | Alimentary Health Limited | Probiotic bifidobacterium strain |
UA109123C2 (uk) | 2010-01-28 | 2015-07-27 | Пробіотична композиція для застосування в лікуванні запалення кишечнику | |
JP4942831B2 (ja) | 2010-03-19 | 2012-05-30 | 株式会社キティー | 抗アレルギー用組成物 |
EP2868206B1 (en) | 2012-07-05 | 2016-09-14 | Centro Nacional De Tecnología Y Seguridad Alimentaria, Laboratorio Del Ebro | Microparticles for the encapsulation of probiotics, preparation and uses thereof |
KR101740583B1 (ko) * | 2014-02-17 | 2017-05-29 | 경희대학교 산학협력단 | 비만 억제 효능을 갖는 신규 유산균 및 이의 용도 |
US9587284B2 (en) * | 2014-02-21 | 2017-03-07 | Asian Probiotics and Prebiotics Ltd. | Lactic acid bacterium having immunomodulatory and anti-allergic effects and pharmaceutical composition containing the same |
KR20160069733A (ko) | 2014-12-09 | 2016-06-17 | (주)바이오리듬 | 신규한 균주로 알러지, 아토피성 피부염, 비염, 가려움증 등의 개선치료 및 면역력조절 기능을 갖는 Lactobacillus plantarum K-1 BR 균주 |
JP2016136890A (ja) | 2015-01-28 | 2016-08-04 | 株式会社ヤクルト本社 | 乳酸菌のインターロイキン10産生誘導能の増強方法 |
KR20170032815A (ko) * | 2015-09-15 | 2017-03-23 | 경희대학교 산학협력단 | 신규 유산균 및 퇴행성 뇌질환 또는 인지기능의 예방, 개선 또는 치료용 조성물 |
KR101655778B1 (ko) | 2016-02-19 | 2016-09-09 | 대한민국 | 락토바실러스 플란타룸 k46 및 이를 포함하는 조성물 |
KR101750468B1 (ko) | 2016-03-04 | 2017-06-27 | 주식회사 메디오젠 | 락토바실러스 퍼멘툼 mg901 또는 락토바실러스 플란타룸 mg989를 포함하는 조성물 |
KR101743044B1 (ko) | 2016-06-28 | 2017-06-02 | 바이오제닉스코리아 주식회사 | 면역증진 및 장내환경개선용 건강기능성 식품 |
-
2018
- 2018-01-31 CA CA3178100A patent/CA3178100A1/en active Pending
- 2018-01-31 US US16/481,643 patent/US11660321B2/en active Active
- 2018-01-31 SG SG10202107425VA patent/SG10202107425VA/en unknown
- 2018-01-31 JP JP2019541313A patent/JP6839298B2/ja active Active
- 2018-01-31 KR KR1020180012186A patent/KR101999259B1/ko active Application Filing
- 2018-01-31 BR BR112019015806-5A patent/BR112019015806A2/pt unknown
- 2018-01-31 CA CA3052134A patent/CA3052134C/en active Active
- 2018-01-31 RU RU2019127021A patent/RU2752157C2/ru active
- 2018-01-31 WO PCT/KR2018/001359 patent/WO2018143678A1/ko unknown
- 2018-01-31 AU AU2018216532A patent/AU2018216532B2/en active Active
- 2018-01-31 CN CN202310634964.0A patent/CN116676222A/zh active Pending
- 2018-01-31 MX MX2019009079A patent/MX2019009079A/es unknown
- 2018-01-31 CN CN201880009638.8A patent/CN110494551B/zh active Active
- 2018-01-31 SG SG11201907043VA patent/SG11201907043VA/en unknown
- 2018-01-31 SG SG10201913050RA patent/SG10201913050RA/en unknown
-
2019
- 2019-07-04 KR KR1020190080934A patent/KR102036841B1/ko active IP Right Grant
- 2019-07-31 MX MX2023003416A patent/MX2023003416A/es unknown
-
2021
- 2021-02-12 JP JP2021020363A patent/JP7124142B2/ja active Active
- 2021-07-15 AU AU2021205078A patent/AU2021205078B2/en active Active
-
2023
- 2023-04-21 US US18/137,541 patent/US20230355690A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2019127021A (ru) | Новые молочнокислые бактерии и их применение | |
AU2016324846B2 (en) | Novel lactobacillus and composition for preventing, improving, or treating degenerative brain diseases or cognitive function disorders | |
US9788557B2 (en) | Lactobacillus classified as Lactobacillus plantarum, and use thereof | |
Ren et al. | Lactobacilli reduce chemokine IL-8 production in response to TNF-α and Salmonella challenge of Caco-2 cells | |
US20120164119A1 (en) | Bacteriocin-producing lactobacillus pentosus and the use thereof in food and pharmaceutical compositions | |
KR102267879B1 (ko) | 신규 유산균, 신규 유산균을 유효 성분으로 하는 자연 면역 활성화제, 및 신규 유산균을 함유하는 음식품 | |
KR102038695B1 (ko) | 프로바이오틱스를 유효성분으로 포함하는 알코올성 장손상 예방 또는 치료용 조성물 | |
KR102135879B1 (ko) | 신규 락토바실러스 플란타룸(Lactobacillus plantarum) KC3 균주를 이용한 면역장애, 호흡기 염증 질환, 알레르기 및 천식의 예방 또는 치료용 조성물 및 이의 용도 | |
KR20190068026A (ko) | 락토바실러스 플란타룸 bk-022 균주 또는 이를 함유하는 항염용 조성물 | |
Lim et al. | Isolation and identification of lactic acid bacteria with probiotic activities from kimchi and their fermentation properties in milk | |
Horie et al. | Regional characteristics of Lactobacillus plantarum group strains isolated from two kinds of Japanese post-fermented teas, Ishizuchi-kurocha and Awa-bancha | |
US9297049B2 (en) | Strain of Lactobacillus mucosae | |
Paray et al. | Pharmaceutical significance of Leuconostoc mesenteroides KS-TN11 isolated from Nile Tilapia, Oreochromis niloticus | |
EP3124599B1 (en) | Lactic acid bacterium belonging to genus weissella | |
Pilasombut et al. | Purification and amino acid sequence of a bacteriocins produced by Lactobacillus salivarius K7 isolated from chicken intestine | |
Wu et al. | Evaluation of the Probiotic Potential of ssp. WDS-7 Isolated from Chinese Traditional Fermented Buffalo Milk | |
JP7090288B2 (ja) | 新規乳酸菌、新規乳酸菌を有効成分として含有する自然免疫活性化剤、及び新規乳酸菌を含有する飲食品 | |
Cho et al. | Characterization of Lactobacillus spp. isolated from the feces of breast-feeding piglets | |
CN102559561B (zh) | 一种食源性乳酸菌及其应用 | |
KR102264825B1 (ko) | 곰보배추 추출물 및 신규 락토바실러스 플란타룸(Lactobacillus plantarum) KC3 균주로 구성된 조합을 유효성분으로 함유하는 면역장애, 호흡기 질환, 알레르기 또는 천식의 예방 및 치료용 조성물 | |
Choi et al. | Studies on the enhanced physiological activities of mixed lactic acid bacteria isolated from fermented watery kimchi, Dongchimi | |
KR101473634B1 (ko) | 프로바이오틱 활성을 갖는 신규 락토바실러스 속 균주 및 이를 이용한 발효홍삼 제조방법 | |
KR101780770B1 (ko) | 한국 전통 간장에서 분리된 신규 바실러스 균주 및 이를 함유하는 프로바이오틱스 | |
Choi et al. | Isolation and characterization of an immune-stimulating lactic acid bacteria from fermenting kimchi | |
US11690883B2 (en) | Lactobacillus acidophilus TW01 isolate and use thereof |